AdipoGenix is focused to the discovery, development and commercialization of novel therapeutics for the treatment of disorders of adipose tissue function such as obesity and diabetes. The company believes that obesity can be treated effectively and safely at the level of the fat cell, rather than indirectly by modulating central nervous system mechanisms. AdipoGenix has developed unique, primary, cellular, HTP-screening assays using the culture of human adipocytes and preadipocytes. These primary cellular screens as well as sub-mitochondrial response screens, and engineered cellular screens are used with a strategy to maximize screening capacity at an early stage in the drug discovery process to identify relevant drug targets and leads.
